In short
A groundbreaking clinical trial is underway to assess the safety and potential effectiveness of GEN1053, a new antibody treatment for patients with malignant solid tumors. This study aims to explore GEN1053 both as a standalone therapy and in combination with an immunomodulator, offering hope for patients who have limited treatment options or have not responded to standard therapies.
At a glance
- Drug Name
- GEN1053 (HexaBody-CD27)
- Trial Phase
- Phase 1/2a
- Target Condition
- Malignant Solid Tumors
- Administration
- Intravenous infusion
- Main Objectives
- Determine safe dose, assess safety profile, evaluate pharmacokinetics and immunogenicity, measure anti-tumor activity
- Study Design
- Open-label, dose-escalation with expansion cohorts
- Treatment Arms
- Monotherapy and combination with immunomodulator
- Key Eligibility
- Adults with measurable disease, progressed on or no standard therapy available
- Primary Endpoints
- Dose-limiting toxicities, adverse events, safety parameters
- Secondary Endpoints
- Pharmacokinetics, immunogenicity, anti-tumor activity (ORR, DCR, DoR)
What is GEN1053?
GEN1053, also known as HexaBody-CD27, is a new experimental drug being developed to treat various types of malignant solid tumors. A malignant solid tumor is a mass of cancerous cells that forms in organs or tissues of the body. This drug is currently being studied in clinical trials to determine its safety and effectiveness in treating cancer patients.
How Does GEN1053 Work?
GEN1053 is a type of drug called an antibody. Antibodies are proteins that help your immune system fight against harmful substances in your body, including cancer cells. This particular antibody targets a protein called CD27, which is found on certain immune cells. By interacting with CD27, GEN1053 aims to boost your immune system's ability to fight cancer.
What Conditions Does GEN1053 Treat?
GEN1053 is being studied for the treatment of various types of malignant solid tumors. This includes, but is not limited to:
- Head and neck squamous cell carcinoma (HNSCC): A type of cancer that begins in the cells that line the mouth, nose, and throat.
- Non-small cell lung cancer (NSCLC): The most common type of lung cancer, accounting for about 80-85% of all cases.
- Other advanced or metastatic solid tumors: This refers to cancers that have spread from where they started to other parts of the body.
Current Research on GEN1053
GEN1053 is currently being studied in a Phase 1/2a clinical trial. This type of trial is designed to:
- Determine the safe dose of GEN1053 (alone and in combination with another drug called an immunomodulator)
- Establish the initial safety profile of the drug
- Understand how the drug moves through and is processed by the body (pharmacokinetics)
- Evaluate how the immune system responds to the drug (immunogenicity)
- Assess the drug's effectiveness in fighting tumors (antitumor activity)
Who Can Participate in GEN1053 Trials?
The current clinical trial for GEN1053 has specific criteria for who can participate. Some key requirements include:
- Being 18 years of age or older
- Having a confirmed diagnosis of a malignant solid tumor
- Having measurable disease according to specific criteria (RECIST 1.1)
- Being in relatively good overall health (ECOG performance status ≤1)
- Having adequate organ function (bone marrow, liver, kidney)
Additionally, participants should have either progressed on standard treatments, have no available standard treatments, or have refused available treatments.
What to Expect During Treatment
If you participate in a GEN1053 clinical trial, you can expect the following:
- GEN1053 is given as an intravenous infusion, which means it's delivered directly into your bloodstream through a vein.
- You may receive GEN1053 alone or in combination with another drug called an immunomodulator.
- Your treatment will be divided into cycles, and you'll have regular check-ups and tests to monitor your progress.
- After your last dose, you'll have follow-up visits at 30 and 60 days to check for any delayed side effects.
Potential Side Effects
As GEN1053 is still in early stages of testing, all potential side effects are not yet known. However, some possible side effects that researchers are monitoring include:
- Immune-related adverse events (irAEs): These are side effects caused by an overactive immune system.
- Changes in blood cell counts
- Changes in liver or kidney function
- Fatigue
- Nausea
- Infusion-related reactions
It's important to note that not everyone will experience these side effects, and there may be others not yet identified. Your healthcare team will monitor you closely for any adverse reactions during the trial.